Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054717 · ClinicalTrials.gov registry record · Phase 3
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
NCT00054717 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 630 participants.
The verdict
NCT00054717, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
Study Summary
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
Interventions
- DRUG Tipranavir
- DRUG Ritonavir(r)
- DRUG Comparator Protease Inhibitor (CPI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054717
The ClinicalTrials.gov registry entry for NCT00054717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tipranavir is the first listed.
NCT00054717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054717 about?
NCT00054717 is a clinical study titled "Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)". Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
What is the current status of trial NCT00054717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2003-01.
What interventions are being tested in trial NCT00054717?
The interventions under investigation include: Tipranavir (DRUG), Ritonavir(r) (DRUG), Comparator Protease Inhibitor (CPI) (DRUG).
Who is sponsoring clinical trial NCT00054717?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.